Impact of COVID-19 2.0 on Indian pharma industry is minimal: ICRA EP News Bureau Jul 2, 2021 FY2022 growth estimated at 7-9 per cent
PLI scheme to help India become Aatmanirbhar in APIs; boost investments in high-value generics: ICRA… EP News Bureau Jun 17, 2021 ICRA expects the above measures to strengthen the business profile of R&D-based Indian pharma companies and thus an increase…
2019-nCoV, nitrosamine issues trigger supply chain re-jigs Viveka Roychowdhury Feb 28, 2020 API manufacturers will have to up their quality game to compete with the new competitors The 2019-nCoV infection, which has…
Pharma margins expected to remain stable in FY2021 despite challenges: ICRA EP News Bureau Jan 28, 2020 Abatement in the US pricing pressure and broad-based growth across markets lead to stable growth during H1 FY2020
ICRA maintains stable outlook for Indian pharma companies EP News Bureau Dec 18, 2019 Domestic pharma cos expected to grow at a CAGR of around 10-12 per cent between FY2019-2022 ICRA has maintained a stable…
Indian pharma industry to grow at 11-13 per cent in FY2020: ICRA Press Trust of India Jul 5, 2019 Moderation in pricing pressure for the US market, new launches and market share gains for existing products and consolidation…
Pharma sector growth likely to remain strong: ICRA Sanjiv Das Oct 5, 2015 The sector has witnessed steady demand across therapy segments, regular new launches and price hikes taken by companies in line…
Generic opportunities outweigh challenges emanating across emerging markets: ICRA Usha Sharma Sep 16, 2015 Supported by acquisitions, geographic expansion and steadily expanding product portfolio, the top-10 pharma companies from India…